Nalbuphine

An opioid analgesic used in pain management

Nalbuphine
Nalbuphine
Chemical nomenclature
IUPAC name	(5α,6α)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol

Nalbuphine is a synthetic opioid used primarily in the management of moderate to severe pain. It is known for its mixed agonist-antagonist properties, which make it unique among opioid analgesics.

Pharmacology

Nalbuphine acts as an agonist at the kappa-opioid receptor and as a partial antagonist at the mu-opioid receptor. This dual action results in effective analgesia with a lower risk of respiratory depression compared to pure mu-opioid agonists like morphine.

Mechanism of Action

Nalbuphine binds to opioid receptors in the central nervous system, altering the perception of and response to pain. Its kappa agonist activity is responsible for its analgesic effects, while its mu antagonist activity helps mitigate some of the adverse effects commonly associated with opioids, such as respiratory depression and euphoria.

Clinical Use

Nalbuphine is used in various clinical settings, including postoperative pain management, labor pain, and as an adjunct to anesthesia. It is administered via intravenous, intramuscular, or subcutaneous injection.

Advantages

One of the main advantages of nalbuphine is its ceiling effect on respiratory depression, which makes it safer in terms of overdose risk compared to other opioids. This property is particularly beneficial in settings where monitoring of respiratory function is limited.

Side Effects

Common side effects of nalbuphine include sedation, dizziness, nausea, and sweating. Due to its partial antagonist properties, it may precipitate withdrawal symptoms in patients who are physically dependent on other opioids.

Regulation and Availability

Nalbuphine is not classified as a controlled substance in many countries, which facilitates its use in various medical settings. However, its availability may vary depending on local regulations and healthcare policies.

Related pages

• Opioid
• Analgesic
• Pain management
• Kappa-opioid receptor
• Mu-opioid receptor